Century Therapeutics (IPSC) Net Cash Flow (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Net Cash Flow of -$11.3 million for Q1 2026, down 71.22% year-over-year from -$39.1 million in Q1 2025, and down 278.27% quarter-over-quarter from $6.3 million in Q4 2025.
Powered by 
Analysis
Century Therapeutics (IPSC) Net Cash Flow (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Net Cash Flow for 7 consecutive years, with -$11.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 71.22% year-over-year to -$11.3 million; the TTM figure through Mar 2026 stood at -$907000.0 (down 115.51% YoY), while the FY2025 annual figure was $3.8 million, down 68.31% from the prior year.
- Net Cash Flow slipped to -$11.3 million in Q1 2026 per IPSC's latest filing, from $6.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $69.6 million in Q1 2022 and bottomed at -$27.1 million in Q4 2022.
- Historically, Net Cash Flow has averaged -$260529.4 across 5 years, with a median of -$1.4 million in 2022.
- Annual changes were most pronounced in 2024 — Net Cash Flow jumped 221.99% — and 2025, when it tumbled 1183.79%.
- Century Therapeutics' Net Cash Flow stood at -$27.1 million in 2022, then soared by 70.53% to -$8.0 million in 2023, then surged by 172.42% to $5.8 million in 2024, then rose by 9.2% to $6.3 million in 2025, then slumped by 278.27% to -$11.3 million in 2026.
- Business Quant data shows IPSC's Net Cash Flow at -$11.3 million in Q1 2026, $6.3 million in Q4 2025, and -$913000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - | -1.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.76 Mn |
| Mar 31, 2026 | -11.25 Mn |
| Dec 31, 2025 | 6.31 Mn |
| Sep 30, 2025 | -913,000.00 |
| Jun 30, 2025 | 4.95 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | 5.78 Mn |
| Sep 30, 2024 | 11.14 Mn |
| Jun 30, 2024 | -4.50 Mn |
| Mar 31, 2024 | -512,000.00 |
| Dec 31, 2023 | -7.98 Mn |
| Sep 30, 2023 | -9.13 Mn |
| Jun 30, 2023 | -22.39 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | -27.09 Mn |
| Sep 30, 2022 | -1.44 Mn |
| Jun 30, 2022 | -12.99 Mn |
| Mar 31, 2022 | 69.59 Mn |
| Dec 31, 2021 | -44.85 Mn |
| Sep 30, 2021 | -171.50 Mn |